Skip to content

Author: Ben Shaberman

FFB-CRI Investing $7.5 Million in Emerging Therapy for USH2A

Source: Foundation Fighting Blindness Blog – Eye on the Cure – FFB-CRI Investing .5 Million in Emerging Therapy for USH2A Audio version: The Foundation Fighting Blindness Clinical Research Institute (FFB-CRI) has entered into a partnership with ProQR to develop a retinal therapy for people with Usher syndrome type 2A…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

AGTC Launches XLRP Gene Therapy Clinical Trial at Five Sites in U.S.

Source: Foundation Fighting Blindness Blog – Eye on the Cure – AGTC Launches XLRP Gene Therapy Clinical Trial at Five Sites in U.S. Audio version:Applied Genetic Technologies Corporation (AGTC) is now recruiting for its Phase 1/2 gene therapy clinical trial for males with X-linked retinitis pigmentosa (XLRP) caused by…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

Ophthotech Launching Human Study of Emerging Therapy for Stargardt Disease

Source: Foundation Fighting Blindness Blog – Eye on the Cure – Ophthotech Launching Human Study of Emerging Therapy for Stargardt Disease Audio Version:Your browser does not support the audio element. Ophthotech, a biopharmaceutical company developing therapies for eye diseases, has enrolled the first patient in its Phase 2b clinical…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

Clinical Trial to Launch for System Combining Optogenetics and Eyewear

Source: Foundation Fighting Blindness Blog – Eye on the Cure – Clinical Trial to Launch for System Combining Optogenetics and Eyewear Audio Version:Your browser does not support the audio element. The French biotech GenSight Biologics has received regulatory authorization in the UK to launch the PIONEER Phase 1/2 clinical…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest